Erratum: Opportunities for therapeutic antibodies directed at G-protein-coupled receptors
Nature Reviews Drug Discovery 16 (2017) In the article, the clinical trial for the biparatopic CXCR2 nanobody was described as being for cancer instead of inflammation. This error has been corrected in the online version.
Gespeichert in:
| Veröffentlicht in: | Nature reviews. Drug discovery 2017-09, Vol.16 (9), p.661-661 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 661 |
|---|---|
| container_issue | 9 |
| container_start_page | 661 |
| container_title | Nature reviews. Drug discovery |
| container_volume | 16 |
| creator | Hutchings, Catherine J. Koglin, Markus Olson, William C. Marshall, Fiona H. |
| description | Nature Reviews Drug Discovery 16 (2017) In the article, the clinical trial for the biparatopic CXCR2 nanobody was described as being for cancer instead of inflammation. This error has been corrected in the online version. |
| doi_str_mv | 10.1038/nrd.2017.173 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref_sprin</sourceid><recordid>TN_cdi_crossref_primary_10_1038_nrd_2017_173</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1038_nrd_2017_173</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1563-86ddce40ca70f8d609b26d84b9cc516c02a3958fac0641a545f58e404897d1943</originalsourceid><addsrcrecordid>eNptkMFOAyEQhonRxFq9-QD7AFJhlwXWm2lqNWnSix48ERZYpWkXMrAH316aNp48zZ_5v0wmH0L3lCwoaeTjCHZREyoWVDQXaEaZYJgKyS7_suDX6CalHSGUU1HP0OcKQOfp8FRtYwyQp9Fn71I1BKjytwMd3ZS9qfSYfR_ssbIenMnOVjpXaxwhZOdHbMIU92VZOhdzgHSLrga9T-7uPOfo42X1vnzFm-36bfm8wYa2vMGSW2scI0YLMkjLSdfX3ErWd8a0lBtS66Zr5aAN4YzqlrVDKwvPZCcs7VgzRw-nuwZCSuAGFcEfNPwoStRRiypa1FGLKloKjk94Ktj45UDtwgRj-fB__hcWi2Yq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Erratum: Opportunities for therapeutic antibodies directed at G-protein-coupled receptors</title><source>Nature Journals Online</source><source>SpringerLink Journals - AutoHoldings</source><creator>Hutchings, Catherine J. ; Koglin, Markus ; Olson, William C. ; Marshall, Fiona H.</creator><creatorcontrib>Hutchings, Catherine J. ; Koglin, Markus ; Olson, William C. ; Marshall, Fiona H.</creatorcontrib><description>Nature Reviews Drug Discovery 16 (2017) In the article, the clinical trial for the biparatopic CXCR2 nanobody was described as being for cancer instead of inflammation. This error has been corrected in the online version.</description><identifier>ISSN: 1474-1776</identifier><identifier>EISSN: 1474-1784</identifier><identifier>DOI: 10.1038/nrd.2017.173</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/154/51/1568 ; 631/45/612/194 ; 692/699/249/2510 ; 692/699/317 ; Biomedical and Life Sciences ; Biomedicine ; Biotechnology ; Cancer Research ; corrigendum ; Erratum ; Medicinal Chemistry ; Molecular Medicine ; Pharmacology/Toxicology</subject><ispartof>Nature reviews. Drug discovery, 2017-09, Vol.16 (9), p.661-661</ispartof><rights>Springer Nature Limited 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1563-86ddce40ca70f8d609b26d84b9cc516c02a3958fac0641a545f58e404897d1943</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/nrd.2017.173$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/nrd.2017.173$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Hutchings, Catherine J.</creatorcontrib><creatorcontrib>Koglin, Markus</creatorcontrib><creatorcontrib>Olson, William C.</creatorcontrib><creatorcontrib>Marshall, Fiona H.</creatorcontrib><title>Erratum: Opportunities for therapeutic antibodies directed at G-protein-coupled receptors</title><title>Nature reviews. Drug discovery</title><addtitle>Nat Rev Drug Discov</addtitle><description>Nature Reviews Drug Discovery 16 (2017) In the article, the clinical trial for the biparatopic CXCR2 nanobody was described as being for cancer instead of inflammation. This error has been corrected in the online version.</description><subject>631/154/51/1568</subject><subject>631/45/612/194</subject><subject>692/699/249/2510</subject><subject>692/699/317</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Cancer Research</subject><subject>corrigendum</subject><subject>Erratum</subject><subject>Medicinal Chemistry</subject><subject>Molecular Medicine</subject><subject>Pharmacology/Toxicology</subject><issn>1474-1776</issn><issn>1474-1784</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNptkMFOAyEQhonRxFq9-QD7AFJhlwXWm2lqNWnSix48ERZYpWkXMrAH316aNp48zZ_5v0wmH0L3lCwoaeTjCHZREyoWVDQXaEaZYJgKyS7_suDX6CalHSGUU1HP0OcKQOfp8FRtYwyQp9Fn71I1BKjytwMd3ZS9qfSYfR_ssbIenMnOVjpXaxwhZOdHbMIU92VZOhdzgHSLrga9T-7uPOfo42X1vnzFm-36bfm8wYa2vMGSW2scI0YLMkjLSdfX3ErWd8a0lBtS66Zr5aAN4YzqlrVDKwvPZCcs7VgzRw-nuwZCSuAGFcEfNPwoStRRiypa1FGLKloKjk94Ktj45UDtwgRj-fB__hcWi2Yq</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Hutchings, Catherine J.</creator><creator>Koglin, Markus</creator><creator>Olson, William C.</creator><creator>Marshall, Fiona H.</creator><general>Nature Publishing Group UK</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20170901</creationdate><title>Erratum: Opportunities for therapeutic antibodies directed at G-protein-coupled receptors</title><author>Hutchings, Catherine J. ; Koglin, Markus ; Olson, William C. ; Marshall, Fiona H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1563-86ddce40ca70f8d609b26d84b9cc516c02a3958fac0641a545f58e404897d1943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>631/154/51/1568</topic><topic>631/45/612/194</topic><topic>692/699/249/2510</topic><topic>692/699/317</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Cancer Research</topic><topic>corrigendum</topic><topic>Erratum</topic><topic>Medicinal Chemistry</topic><topic>Molecular Medicine</topic><topic>Pharmacology/Toxicology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hutchings, Catherine J.</creatorcontrib><creatorcontrib>Koglin, Markus</creatorcontrib><creatorcontrib>Olson, William C.</creatorcontrib><creatorcontrib>Marshall, Fiona H.</creatorcontrib><collection>CrossRef</collection><jtitle>Nature reviews. Drug discovery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hutchings, Catherine J.</au><au>Koglin, Markus</au><au>Olson, William C.</au><au>Marshall, Fiona H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Erratum: Opportunities for therapeutic antibodies directed at G-protein-coupled receptors</atitle><jtitle>Nature reviews. Drug discovery</jtitle><stitle>Nat Rev Drug Discov</stitle><date>2017-09-01</date><risdate>2017</risdate><volume>16</volume><issue>9</issue><spage>661</spage><epage>661</epage><pages>661-661</pages><issn>1474-1776</issn><eissn>1474-1784</eissn><abstract>Nature Reviews Drug Discovery 16 (2017) In the article, the clinical trial for the biparatopic CXCR2 nanobody was described as being for cancer instead of inflammation. This error has been corrected in the online version.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><doi>10.1038/nrd.2017.173</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1474-1776 |
| ispartof | Nature reviews. Drug discovery, 2017-09, Vol.16 (9), p.661-661 |
| issn | 1474-1776 1474-1784 |
| language | eng |
| recordid | cdi_crossref_primary_10_1038_nrd_2017_173 |
| source | Nature Journals Online; SpringerLink Journals - AutoHoldings |
| subjects | 631/154/51/1568 631/45/612/194 692/699/249/2510 692/699/317 Biomedical and Life Sciences Biomedicine Biotechnology Cancer Research corrigendum Erratum Medicinal Chemistry Molecular Medicine Pharmacology/Toxicology |
| title | Erratum: Opportunities for therapeutic antibodies directed at G-protein-coupled receptors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T15%3A22%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref_sprin&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Erratum:%20Opportunities%20for%20therapeutic%20antibodies%20directed%20at%20G-protein-coupled%20receptors&rft.jtitle=Nature%20reviews.%20Drug%20discovery&rft.au=Hutchings,%20Catherine%20J.&rft.date=2017-09-01&rft.volume=16&rft.issue=9&rft.spage=661&rft.epage=661&rft.pages=661-661&rft.issn=1474-1776&rft.eissn=1474-1784&rft_id=info:doi/10.1038/nrd.2017.173&rft_dat=%3Ccrossref_sprin%3E10_1038_nrd_2017_173%3C/crossref_sprin%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |